GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Response Genetics Inc (OTCPK:RGDXQ) » Definitions » Cash Flow from Operations

Response Genetics (Response Genetics) Cash Flow from Operations : $-11.12 Mil (TTM As of Mar. 2015)


View and export this data going back to 2007. Start your Free Trial

What is Response Genetics Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Mar. 2015, Response Genetics's Net Income From Continuing Operations was $-4.02 Mil. Its Depreciation, Depletion and Amortization was $0.19 Mil. Its Change In Working Capital was $-0.10 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.00 Mil. Its Stock Based Compensation was $0.11 Mil. And its Cash Flow from Others was $1.93 Mil. In all, Response Genetics's Cash Flow from Operations for the three months ended in Mar. 2015 was $-1.88 Mil.


Response Genetics Cash Flow from Operations Historical Data

The historical data trend for Response Genetics's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Response Genetics Cash Flow from Operations Chart

Response Genetics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.08 -8.01 -8.08 -12.34 -13.60

Response Genetics Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Dec15
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.18 -4.30 -1.76 -1.88 -

Response Genetics Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Response Genetics's Cash Flow from Operations for the fiscal year that ended in Dec. 2015 is calculated as:

Response Genetics's Cash Flow from Operations for the quarter that ended in Mar. 2015 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Response Genetics  (OTCPK:RGDXQ) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Response Genetics's net income from continuing operations for the three months ended in Mar. 2015 was $-4.02 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Response Genetics's depreciation, depletion and amortization for the three months ended in Mar. 2015 was $0.19 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Response Genetics's change in working capital for the three months ended in Mar. 2015 was $-0.10 Mil. It means Response Genetics's working capital declined by $0.10 Mil from Dec. 2014 to Mar. 2015 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Response Genetics's cash flow from deferred tax for the three months ended in Mar. 2015 was $0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Response Genetics's cash from discontinued operating Activities for the three months ended in Mar. 2015 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Response Genetics's asset impairment charge for the three months ended in Mar. 2015 was $0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Response Genetics's stock based compensation for the three months ended in Mar. 2015 was $0.11 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Response Genetics's cash flow from others for the three months ended in Mar. 2015 was $1.93 Mil.


Response Genetics Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Response Genetics's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Response Genetics (Response Genetics) Business Description

Traded in Other Exchanges
N/A
Address
201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.
Executives
Roberto Mignone 10 percent owner C/O BRIDGER MANAGEMENT, LLC., 90 PARK AVENUE, 40TH FL., NEW YORK NY 10016
Bridger Management Llc 10 percent owner 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Swiftcurrent Offshore Ltd 10 percent owner C/O MAPLES CORPORATE SERVICES LIMITED, UGLAND HOUSE, PO BOX 309, GRAND CAYMAN E9 KY1-1104
David Schreiber director 15 TROTTERS LANE, MONROE CT 06468
Sam Chawla director 1640 MARENGO STREET, 6TH FLOOR, LOS ANGELES CA 90033
Van Den Broek Richard director 73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Kevin Roy Harris officer: Vice President and CFO 345 N MAPLE DRIVE, SUITE 120, BEVERLY HILLS CA 90210
Kirk K Calhoun director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Michael Serruya director C/O RESPONSE GENETICS, INC., 1640 MARENGO ST., 6TH FLOOR, LOS ANGELES CA 90033
Thomas A Bologna director, officer: Chief Executive Officer 4390 US ROUTE ONE, PRINCETON NJ 08540
Marxe Austin W & Greenhouse David M 10 percent owner C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Partners Swiftcurrent 10 percent owner 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Bridger Capital Llc 10 percent owner 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Michael A Metzger director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451

Response Genetics (Response Genetics) Headlines

From GuruFocus

Response Genetics Inc. (RGDX) CFO Thomas Stankovich buys 7,000 Shares

By GuruFocus Research GuruFocus Editor 12-14-2009